Skip to main content
. Author manuscript; available in PMC: 2014 Nov 6.
Published in final edited form as: Circulation. 2014 Feb 19;129(18):1850–1859. doi: 10.1161/CIRCULATIONAHA.113.005754

Table 4.

Outcomes in the TI Population

Events Rivaroxaban (n=2165 Patients, 3393 TIs)
Warfarin (n=2527 Patients, 4162 TIs)
HR (CI) for Rivaroxaban vs Warfarin P Value
No. of Events Event Rate per 30 d, % No. of Events Event Rate per 30 d %
Stroke/systemic embolism 12 0.30 20 0.41 0.74 (0.36, 1.50) 0.40
Death 7 0.17 9 0.18 0.93 (0.34, 2.56) 0.89
MI 11 0.28 18 0.37 0.75 (0.36, 1.59) 0.46
Stroke/systemic embolism/MI/death 26 0.66 46 0.95 0.70 (0.43, 1.13) 0.14
Major/NMCR bleeding 95 3.33 111 3.00 1.12 (0.85, 1.47) 0.43
Major bleeding 37 0.99 37 0.79 1.26 (0.80, 2.00) 0.32

Stroke/systemic embolism/MI/death as a composite does not include multiple events in the same patient. CI indicates confidence interval; HR, hazard ratio; MI, myocardial infarction; NMCR, nonmajor clinically relevant; and TI, temporary interruption.